Exclusive Report: Pharma IP Rights At Risk In Asia
This article was originally published in PharmAsia News
Executive Summary
Rockville, Md. (April 9, 2007) PharmAsia News announces the publication of an exclusive report: Pharma IP Rights At Risk In Asia. The report examines the ongoing compulsory license dispute in Thailand, where the government recently issued compulsory licenses for brand name drugs manufactured by Abbott, Merck and Sanofi-Aventis
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)